• Serum thymidine kinase activity in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with palbociclib and fulvestrant 

  Bliss, J
• Combined Peri-operative Lapatinib and Trastuzumab in Early HER2 Positive Breast Cancer can Identify Early Responders: Results from the UK EPHOS-B Trial (CRUK/08/002 

  Bliss, J; Porta, N; Emson, M; Miller, S; Morden, J
• Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study 

  Fendler, A; Au, L; Shepherd, STC; Byrne, F; Cerrone, M; Boos, LA; Rzeniewicz, K; Gordon, W; Shum, B; Gerard, CL; Ward, B; Xie, W; Schmitt, AM; Joharatnam-Hogan, N; Cornish, GH; Pule, M; Mekkaoui, L; Ng, KW; Carlyle, E; Edmonds, K; Rosario, LD; Sarker, S; Lingard, K; Mangwende, M; Holt, L; Ahmod, H; Stone, R; Gomes, C; Flynn, HR; Agua-Doce, A; Hobson, P; Caidan, S; Howell, M; Wu, M; Goldstone, R; Crawford, M; Cubitt, L; Patel, H; Gavrielides, M; Nye, E; Snijders, AP; MacRae, JI; Nicod, J; Gronthoud, F; Shea, RL; Messiou, C; Cunningham, D; Chau, I; Starling, N; Turner, N; Welsh, L; van As, N; Jones, RL; Droney, J; Banerjee, S; Tatham, KC; Jhanji, S; O’Brien, M; Curtis, O; Harrington, K; Bhide, S; Bazin, J; Robinson, A; Stephenson, C; Slattery, T; Khan, Y; Tippu, Z; Leslie, I; Gennatas, S; Okines, A; Reid, A; Young, K; Furness, AJS; Pickering, L; Gandhi, S; Gamblin, S; Swanton, C; Nicholson, E; Kumar, S; Yousaf, N; Wilkinson, KA; Swerdlow, A; Harvey, R; Kassiotis, G; Larkin, J; Wilkinson, RJ; Turajlic, S

  <jats:title>Abstract</jats:title><jats:p>Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. ...
• Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). 

  Popat, S; Liu, G; Lu, S; Song, G; Ma, X; Yang, JC-H

  Crizotinib is highly efficacious and more tolerable than chemotherapy for ALK⁺ non-small-cell lung cancer (NSCLC), but its progression-free survival benefit and intracranial efficacy have limitations. Head-to-head ...
• Non-randomised comparison of efficacy and side effects of bicalutamide compared with LHRH analogues in combination with radiotherapy in the CHHiP trial. 

  Tree, A; Griffin, C; Syndikus, I; Birtle, A; Choudhury, A; Graham, J; Ferguson, C; Khoo, V; Malik, Z; O'Sullivan, J; Panades, M; Parker, C; Rimmer, Y; Scrase, C; Staffurth, J; Dearnaley, D; Hall, E
• Treatment Response Assessment Maps (TRAMs), a new tool for CNS lymphoma 

  Millard, T; Chau, I; Iyengar, S; El‐Sharkawi, D; Cunningham, D; Sharma, B
• A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. 

  Collins, GP; Eyre, TA; Schmitz-Rohmer, D; Townsend, W; Popat, R; Giulino-Roth, L; Fields, PA; Krasniqi, F; Soussain, C; Stathis, A; Andjelkovic, N; Cunningham, D; Mandic, D; Radulovic, S; Tijanic, I; Horowitz, NA; Kurtovic, S; Schorb, E; Schmidt, C; Dimitrijević, S; Dreyling, M

  Bimiralisib is an orally bioavailable pan-phosphatidylinositol 3-kinase and mammalian target of rapamycin inhibitor which has shown activity against lymphoma in preclinical models. This phase I/II study evaluated the ...
• Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations. 

  Curcean, S; Cheng, L; Picchia, S; Tunariu, N; Collins, D; Blackledge, M; Popat, S; O'Brien, M; Minchom, A; Leach, MO; Koh, D-M

  Introduction We compared the magnetic resonance imaging total tumor volume (TTV) and median apparent diffusion coefficient (ADC) of malignant pleural mesothelioma (MPM) before and at 4 weeks after chemotherapy, to evaluate ...
• Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. 

  Stankunaite, R; George, SL; Gallagher, L; Jamal, S; Shaikh, R; Yuan, L; Hughes, D; Proszek, PZ; Carter, P; Pietka, G; Heide, T; James, C; Tari, H; Lynn, C; Jain, N; Portela, LR; Rogers, T; Vaidya, SJ; Chisholm, JC; Carceller, F; Szychot, E; Mandeville, H; Angelini, P; Jesudason, AB; Jackson, M; Marshall, LV; Gatz, SA; Anderson, J; Sottoriva, A; Chesler, L; Hubank, M (2021-12-18)

  <h4>Objective</h4>Clinical diagnostic sequencing of circulating tumour DNA (ctDNA) is well advanced for adult patients, but application to paediatric cancer patients lags behind.<h4>Methods</h4>To address this, we have ...
• Treatments and Outcomes in Oligometastatic Soft Tissue Soft Sarcoma - A Single Centre Retrospective Analysis. 

  Walls, GM; Zaidi, SH; Fotiadis, N; Jordan, S; Maruzzo, M; Hamid, I; Al-Muderis, O; Khabra, K; Benson, C; Jones, RL; Judson, IR; Miah, AB

  <h4>Background/aim</h4>Distinguishing true oligometastatic disease from early polymetastatic disease is vital in patients with soft tissue sarcoma as contemporary treatment strategies differ significantly. Clinical factors ...
• Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. 

  Vincenzi, B; Napolitano, A; Fiocco, M; Mir, O; Rutkowski, P; Blay, J-Y; Reichardt, P; Joensuu, H; Fumagalli, E; Gennatas, S; Hindi, N; Nannini, M; Spalato Ceruso, M; Italiano, A; Grignani, G; Brunello, A; Gasperoni, S; De Pas, T; Badalamenti, G; Pantaleo, MA; van Houdt, WJ; IJzerman, NS; Steeghs, N; Gelderblom, H; Desar, IME; Falkenhorst, J; Silletta, M; Sbaraglia, M; Tonini, G; Martin-Broto, J; Hohenberger, P; Le Cesne, A; Jones, RL; Dei Tos, AP; Gronchi, A; Bauer, S; Casali, PG (2021-10-06)

  <h4>Purpose</h4>The effect of high-dose imatinib (800 mg/day) on survival in the adjuvant treatment of patients with resected KIT exon 9-mutated gastrointestinal stromal tumors (GIST) is not established. Here, the association ...
• Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study 

  Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; Byrne, F; Cerrone, M; Schmitt, AM; Joharatnam-Hogan, N; Shum, B; Tippu, Z; Rzeniewicz, K; Boos, LA; Harvey, R; Carlyle, E; Edmonds, K; Del Rosario, L; Sarker, S; Lingard, K; Mangwende, M; Holt, L; Ahmod, H; Korteweg, J; Foley, T; Bazin, J; Gordon, W; Barber, T; Emslie-Henry, A; Xie, W; Gerard, CL; Deng, D; Wall, EC; Agua-Doce, A; Namjou, S; Caidan, S; Gavrielides, M; MacRae, J; Kelly, G; Peat, K; Kelly, D; Murra, A; Kelly, K; O'Flaherty, M; Dowdie, L; Ash, N; Gronthoud, F; Shea, RL; Gardner, G; Murray, D; Kinnaird, F; Cui, W; Pascual, J; Rodney, S; Mencel, J; Curtis, O; Stephenson, C; Robinson, A; Oza, B; Farag, S; Leslie, I; Rogiers, A; Iyengar, S; Ethell, M; Messiou, C; Cunningham, D; Chau, I; Starling, N; Turner, N; Welsh, L; van As, N; Jones, RL; Droney, J; Banerjee, S; Tatham, KC; O'Brien, M; Harrington, K; Bhide, S; Okines, A; Reid, A; Young, K; Furness, AJS; Pickering, L; Swanton, C; Gandhi, S; Gamblin, S; Bauer, DL; Kassiotis, G; Kumar, S; Yousaf, N; Jhanji, S; Nicholson, E; Howell, M; Walker, S; Wilkinson, RJ; Larkin, J; Turajlic, S (NATURE PORTFOLIO, 2021-10-27)
• RE-ARMing the immune response to bladder cancer with radiotherapy 

  Hall, E; Wilkins, A; Lewis, R; Gribble, H; Huddart, R; Melcher, A
• Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial 

  Copland, M; Slade, D; McIlroy, G; Horne, G; Byrne, JL; Rothwell, K; Brock, K; De Lavallade, H; Craddock, C; Clark, RE; Smith, ML; Fletcher, R; Bishop, R; Milojkovic, D; Yap, C
• Exploring novel approaches to metastatic heterogeneity and clonal evolution 

  Spain, L (2021-12-31)

  Background Alternative methods are required to optimise the clinical insights that may be derived from studies of cancer evolution and heterogeneity. Profiling a single biopsy of tumour tissue underestimates potential ...
• Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). 

  Popat, S; Jung, HA; Lee, SY; Hochmair, MJ; Lee, SH; Escriu, C; Lee, MK; Migliorino, MR; Lee, YC; Girard, N; Daoud, H; Märten, A; Miura, S (2021-09-21)

  Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However, optimal sequence of treatment has yet to be ...
• Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer. 

  Haynes, BP; Schuster, G; Buus, R; Alataki, A; Ginsburg, O; Quang, LH; Han, PT; Khoa, PH; Van Dinh, N; Van To, T; Clemons, M; Holcombe, C; Osborne, C; Evans, A; Skene, A; Sibbering, M; Rogers, C; Laws, S; Noor, L; Cheang, MCU; Cleator, SJ; Smith, IE; Dowsett, M

  Purpose Changes occur in the expression of oestrogen-regulated and proliferation-associated genes in oestrogen receptor (ER)-positive breast tumours during the menstrual cycle. We investigated if Oncotype® DX recurrence ...
• Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. 

  Camidge, DR; Kim, HR; Ahn, M-J; Yang, JCH; Han, J-Y; Hochmair, MJ; Lee, KH; Delmonte, A; Garcia Campelo, MR; Kim, D-W; Griesinger, F; Felip, E; Califano, R; Spira, AI; Gettinger, SN; Tiseo, M; Lin, HM; Liu, Y; Vranceanu, F; Niu, H; Zhang, P; Popat, S (2021-09-16)

  Introduction In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced ALK-positive NSCLC, brigatinib exhibited superior ...
• Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogenous KIT/PDGFRA mutations in the phase 3 INVICTUS study. 

  Bauer, S; Heinrich, MC; George, S; Zalcberg, JR; Serrano, C; Gelderblom, H; Jones, RL; Attia, S; D'Amato, G; Chi, P; Reichardt, P; Meade, J; Su, Y; Ruiz-Soto, R; Blay, J-Y; von Mehren, M; Schöffski, P (2021-09-09)

  Purpose Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in KIT/PDGFRA and are initially responsive to tyrosine kinase inhibitors (TKIs). The acquisition of secondary mutations leads to ...
• Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors 

  Doz, F; van Tilburg, CM; Geoerger, B; Højgaard, M; Øra, I; Boni, V; Capra, M; Chisholm, J; Chung, HC; DuBois, SG; Gallego-Melcon, S; Gerber, NU; Goto, H; Grilley-Olson, JE; Hansford, JR; Hong, DS; Italiano, A; Kang, HJ; Nysom, K; Thorwarth, A; Stefanowicz, J; Tahara, M; Ziegler, DS; Gavrilovic, IT; Norenberg, R; Dima, L; De La Cuesta, E; Laetsch, TW; Drilon, A; Perreault, S

  Abstract Background Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was ...

View more